Rucaparib + Nivolumab for Biliary Tract Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests if using rucaparib and nivolumab together can help patients with Biliary Tract Cancer live longer. Rucaparib stops cancer cells from repairing themselves, and nivolumab boosts the immune system to fight the cancer.
Who Is on the Research Team?
Vaibhav Sahai, MBBS, MS
Principal Investigator
Rogel Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults with advanced biliary tract cancer who've had platinum-based chemotherapy but can't have surgery or other curative treatments. They must be in good physical condition, not have certain other cancers or serious medical issues, and agree to use effective contraception.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Rucaparib 600 mg PO BID days 1-28 and Nivolumab 240 mg IV days 1 and 15
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Nivolumab
- Rucaparib
Nivolumab is already approved in United States, European Union, Canada, Switzerland for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Michigan Rogel Cancer Center
Lead Sponsor
Dana-Farber Cancer Institute
Collaborator
Vanderbilt University Medical Center
Collaborator